Advertisement

Topics

Efficacy and Safety of Lercanidipine and Enalapril in Patients With Essential Hypertension

2014-08-27 03:14:58 | BioPortfolio

Summary

The poupose of this study is to evaluate the efficacy and safety of various dosage combinations of lercanidipine (10 and 20 mg)and enalapril (10 and 20 mg) in comparison with their respective components and with placebo.

Study Design

Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Conditions

Essential Hypertension

Intervention

Placebo, Lercanidipine, Lercanidipine, Enalapril, Enalapril, Lercanidipine + Enalapril, Lercanidipine + Enalapril, Lercanidipine + Enalapril, Lercanidipine + Enalapril

Location

Hôpital de la Pitié-Salpétrière
Paris
France

Status

Recruiting

Source

Recordati Industria Chimica e Farmaceutica S.p.A.

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:14:58-0400

Clinical Trials [73 Associated Clinical Trials listed on BioPortfolio]

Efficacy and Safety of Lercanidipine and Valsartan in Patients With Essential Hypertension

The purpose of this study is to evaluate the safety and efficacy of fixed combination of lercanidipine (10 mg or 20 mg) and valsartan (80 mg or 160 mg), lercanidipine and valsartan alone i...

Bariatric Surgery and Pharmacokinetics of Lercanidipine

Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of ...

Effects of Antihypertensive Treatment in HIV Infected Patients: Candesartan Versus Lercanidipine

Human immunodeficiency virus infection and highly active antiretroviral therapy (HAART) are associated with an increased risk of cardiovascular disease: a wide range of alterations in lip...

Enalapril After Anthracycline Cardiotoxicity

To determine if the chronic administration of enalapril, an inhibitor of angiotensin converting enzyme (ACE), reduces progression of cardiac dysfunction in pediatric oncology patients who ...

Extension Study to Assess Long Term Safety, Tolerability and Efficacy of Valsartan and Enalapril Combined and Alone in Children With Hypertension

The purpose of this extension study is to compare the long term safety of valsartan versus enalapril, and the effectiveness of the combination of valsartan and enalapril versus enalapril a...

PubMed Articles [913 Associated PubMed Articles listed on BioPortfolio]

Lercanidipine and T-type calcium current.

Lercanidipine is a calcium antagonist with no cardiodepressant activity, long lasting antihypertensive action and reno-protective effect. Our previous data demonstrated that lercanidipine blocks L-typ...

Flexible and precise dosing of enalapril maleate for all paediatric age groups utilizing orodispersible minitablets.

Enalapril is an off-patent angiotensin-converting enzyme inhibitor for which no paediatric age-appropriate formulation is commercially available in Europe, and enalapril maleate (EM) orodispersible mi...

Sacubitril/Valsartan: potential treatment for paediatric heart failure.

The Prospective comparison of angiotensin receptor antagonist Valsartan and neprilysin inhibitor Sacubitril with angiotensin-converting enzyme inhibitor (enalapril) to determine impact on Global Morta...

Was the Enalapril Dose Too Low in the PARADIGM-HF Trial?

Heart failure (HF) is a common clinical syndrome associated with significant morbidity and mortality, and there remains a clear need for innovative therapies that can modify disease progression. Sacub...

Continuous Inkjet Printing of Enalapril Maleate onto Orodispersible Film Formulations.

Piezoelectric inkjet printing onto orodispersible films (ODFs) was proven to be a successful technique applying flexible doses of active pharmaceutical ingredients (APIs) onto edible substrates. The r...

Medical and Biotech [MESH] Definitions

One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS that is used to treat hypertension.

The active metabolite of ENALAPRIL and a potent intravenously administered angiotensin-converting enzyme inhibitor. It is an effective agent for the treatment of essential hypertension and has beneficial hemodynamic effects in heart failure. The drug produces renal vasodilation with an increase in sodium excretion.

Misunderstanding among individuals, frequently research subjects, of scientific methods such as randomization and placebo controls.

An effect usually, but not necessarily, beneficial that is attributable to an expectation that the regimen will have an effect, i.e., the effect is due to the power of suggestion.

More From BioPortfolio on "Efficacy and Safety of Lercanidipine and Enalapril in Patients With Essential Hypertension"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial